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Abstract
Background: In Cape Town, the roll-out of antiretroviral therapy (ART) has increased over the last decade with an
estimated coverage of 63% of HIV- positive patients in 2013. The influence of ART on the characteristics of the
population of HIV-positive patients presenting to the primary care TB programme is unknown. In this study, we
examined trends in CD4 count distribution, ART usage and treatment outcomes among HIV-positive TB patients in
Cape Town from 2009 to 2013.
Methods: Data from the electronic TB register on all newly registered drug-sensitive TB patients ≥18 years were
analyzed retrospectively. Descriptive statistics were used to compare baseline characteristics, the CD4 count
distribution and TB treatment outcomes both by year of treatment and ART status at the start of TB treatment.
Survival analyses were used to assess the change in mortality risk during TB treatment over time, stratified by ART
status at start of TB treatment.
Results: 118,989 patients were treated over 5 years. HIV prevalence among TB patients decreased from 50.9% in 2009
to 49.0% in 2013. The absolute number of HIV-positive TB cases declined by 13.2% between 2010 and 2013. More
patients entered the TB programme on ART in 2013 compared to 2009 (30.0% vs 9.9%). Among these, the CD4 count
distribution showed a year by year shift to higher CD4 counts. In 2013, over 75% of ART-naïve TB patients still had a
CD4 count < 350 cells/mm3. ART initiation among ART-naive patients increased from 37.0 to 77.7% and TB case fatality
declined from 7.4 to 5.2% (p < 0.001). In multivariate analysis a decrease in TB mortality was most strongly associated
with CD4 count (Adjusted HR 0.82 per increase of 50 cells/mm3, 95% CI: 0.81–0.83, p < 001) and the initiation of ART
during TB treatment (Adjusted HR 0.39, 95% CI: 0.35–0.42, p < 0.001).
Conclusion: Comprehensive changes in the ART and TB treatment programmes resulted in incremental increases in
ART coverage for HIV-positive TB patients and a subsequent decrease in TB case fatality due to increased ART uptake in
HIV-positive ART-naïve patients. However TB still remained a major presenting opportunistic infection with the majority
of cases occurring at low CD4 counts.
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Background
In sub-Saharan Africa, the increase in the tuberculosis
(TB) epidemic has been shown to strongly correlate with
the increase in HIV-prevalence [1, 2]. This has been
driven predominantly by a rise in HIV-positive TB cases
among patients with severe immune suppression [2].
Public health interventions aimed at reducing TB inci-
dence rates have included the WHO three I’s strategy of
intensified case-finding, isoniazid preventive therapy and
infection control as well as wide-scale antiretroviral ther-
apy (ART) for HIV-positive patients [3]. In HIV-positive
patients, ART has been shown to be strongly associated
with a reduction in TB incidence rates [4]. However,
previous studies of HIV/TB co-infected patients in
sub-Saharan Africa have shown that most patients diag-
nosed with TB had low CD4 counts and were not receiv-
ing ART at the time of TB diagnosis [5–7].
In South Africa, the coverage of the ART rollout has
increased substantially over the last decade [8]. In Cape
Town with an HIV prevalence of 5.2% in 2013, the
roll-out of ART in primary health care clinics was esti-
mated to provide coverage of 63% of HIV-positive pa-
tients in that same year [9]. While the increase in
coverage has been shown to coincide with a decline in
the HIV-positive TB epidemic in the city, the influence
of ART on the characteristics of the HIV-positive pa-
tients presenting with TB is unknown.
This study therefore aimed to determine the annual
changes in HIV prevalence, CD4 count distribution,
ART initiation and TB treatment outcomes among
HIV-positive TB patients as well as the risk factors for
TB case fatality in this cohort of patients receiving TB
treatment in Cape Town from 2009 to 2013.
Methods
Setting and treatment
In Cape Town, TB treatment is provided in 101 primary
care clinics by nursing staff with support from medical
officers. During the period of the study, forty of these
clinics also provided antiretroviral therapy with the re-
mainder referring patients off- site for ART.
ART eligibility criteria and treatment regimens for
HIV/TB co-infected patients changed twice during the
period of the study. Prior to mid-2010, ART initiation
was recommended for adult HIV-positive patients with a
CD4 count <200copies/mm3 or WHO Stage 4 disease.
The recommended first line treatment regimens were
stavudine or zidovudine with lamivudine and efavirenz
or nevirapine [10]. In 2010, updated South African ART
guidelines extended the CD4 eligibility criteria to
<350cells/mm3 and recommended a first line regimen of
tenofovir, lamivudine and efavirenz and in August 2012,
the guidelines were amended again to provide ART for
all TB/HIV co-infected patients irrespective of the CD4
count [11, 12]. Second line ART was either zidovudine
or tenofovir depending on prior exposure during first
line treatment plus lamivudine and lopinavir/ritonavir.
Due to rifampicin interactions with protease inhibitors,
patients with TB on second line ART had the lopinavir/
ritonavir boosted with extra ritonavir or the dose dou-
bled slowly over a 3 week period [10, 11].
TB diagnosis and treatment guidelines also changed
during the study period. Up to 2011, microbiological TB
confirmation was determined through sputum smear
microscopy or TB culture. [13] From August 2011, Gen-
eXpert MTB/RIF was rolled out and by February 2013 it
had completely replaced smear microscopy as the pri-
mary test for TB [14]. During the study period, new TB
patients received treatment with a daily fixed dose com-
bination tablet of rifampicin, isoniazid, pyrazinamide
and ethambutol (RHZE) during the intensive phase of
TB treatment followed by rifampicin and isoniazid (RH)
in the continuation phase. Prior to 2013, retreatment TB
patients received streptomycin 5 days a week for
2 months, rifampicin, isoniazid, pyrazinamide and eth-
ambutol daily for 3 months, followed by rifampicin, iso-
niazid and ethambutol for a further 5 months. [13] In
2013, streptomycin was phased out and all patients with
drug sensitive TB received RHZE in the intensive phase
and RH in the continuation phase [14].
Study design and population
This was a retrospective cohort analysis of newly regis-
tered drug sensitive TB patients ≥18 years. The data for
the analysis was extracted from the electronic TB register
(ETR.net) for Cape Town which is a database of case re-
cords of all patients who received TB treatment in primary
care TB clinics in Cape Town. Included in the study were
adult patients who started TB treatment in any of Cape
Town’s primary health care TB treatment facilities from 1
January 2009 to 31 December 2013. To avoid duplication
of cases, patients who transferred between primary care
TB clinics for treatment were excluded. Although patients
with drug resistant TB were not routinely entered into the
ETR.net database, some patients in the database were sub-
sequently noted to have drug resistant TB. These patients
were also excluded from the analysis.
Operational definitions
The TB definitions of TB treatment outcomes were ac-
cording to the 2009 WHO TB Treatment Guidelines.
[15] TB success was defined as the summation of cure
and completion. TB case fatality was defined as death
during TB treatment irrespective of cause of death. Pa-
tients who did not have a TB treatment outcome were
recorded as “not evaluated”.
The HIV status of a patient was defined as positive if
the patient was recorded to have a positive HIV test
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result at the beginning of TB treatment, or was recorded
as receiving ART and/or co-trimoxazole prophylaxis
and/or had a recorded CD4 cell count result at start of
TB treatment. HIV-negative status was defined by a
HIV-negative test result recorded in the database. All
other patients were considered to be of unknown HIV
status.
Data analysis
Descriptive statistics were used to compare baseline
characteristics, the CD4 count distribution and TB treat-
ment outcomes both by year of treatment and ART sta-
tus at the start of TB treatment. These were summarised
as proportions for categorical variables and medians
with inter-quartile ranges (IQRs) for continuous vari-
ables. Differences in HIV prevalence and median CD4
counts over time were tested using the chi-square test
for trend and the Cuzick nonparametric test for trend
respectively. Survival analyses were used to assess the
change in mortality risk during TB treatment over time
stratified by ART status at start of TB treatment
(log-rank test for equality in survivor function). Censor-
ing occurred at dates of death, default, transfer out, fail-
ure, cure or completion. Uni- and multivariable Cox
proportional hazard models were used to determine risk
factors for TB mortality in the HIV-positive patients on
ART at start of TB treatment and not on ART at start of
TB treatment. The proportionality assumption was
assessed visually using –ln((−ln(survival)) plots. The
analyses were performed using Stata IC 13.0 (StataCorp,
USA).
Ethics approval
The Cape Town City Health Directorate approved the use
of an anonymised database of routinely collected TB data
for this analysis. As the data used in this analysis were col-
lected as part of the routine monitoring and evaluation of
the South African National TB programme, patients were
not requested to provide informed consent for the use of
their data. Confidentiality was ensured through the re-
moval of patient identifiers prior to the analysis. This
study was approved by the University of Cape Town
Research Ethics Committee.
Results
Cohort characteristics
Over the 5 year study period from 1 Jan 2009 to 31 Dec
2013, 149,360 TB patients were treated in 101 primary
care clinics in Cape Town. Of these, 30,371 were ex-
cluded from this analysis as they were under the age of
18 (n = 22,468) or transferred care between the primary
care TB clinics (n = 6746) or were found to have had
drug resistant TB (n = 1157). Of the remaining 118,989
newly registered adult patients with drug sensitive TB,
60482 (50.8%) were HIV-positive and formed the cohort
for this analysis (Additional file 1: Appendix 1). The re-
mainder were either HIV-negative [55,377 (46.5%)] or
had an unknown HIV status [3130 (2.6%)]. The HIV
prevalence among TB patients decreased from 50.9% in
2009 to 49.0% in 2013. The absolute numbers of adult
TB cases increased by 1.7% from 24,291 in 2009 to a
peak of 24,697 in 2010 and then declined by 8.6% to
22,585 cases in 2013. This was largely due to a decline
in HIV-positive TB cases. These first increased by 3.0%
from 12,372 in 2009 to 12,749 in 2010 and then de-
creased by 13.2% to 11,060 in 2013. Over the same time
period, HIV-negative TB cases increased by 5.6% from
10,673 in 2009 to 11,276 in 2010 with a marginal de-
crease of 54 cases (0.5%) between 2010 and 2013. The
analysis of the 60,482 HIV-positive TB patients showed
that 11,708 (19.4%) were on ART at the start of TB treat-
ment while 48,749 (80.6%) were not on ART at the start
of TB treatment.
HIV-positive patients on ART
The patient characteristics of this cohort are shown by
year in Table 1a. The proportion of patients on ART at
the start of TB treatment increased over the 5 years
from 9.9% in 2009 to 30.0% in 2013. The median age
was 35 [interquartile range (IQR) 30–41 years] and 6799
(58.1%) were female. The proportion of extra-pulmonary
TB cases decreased from 27.5% in 2009 to 16.8% in
2013. Over this time period, the median CD4 count at
the start of TB treatment increased from 150 [IQR
74–242 cells/mm3] to 202 [IQR 91–348 cells/mm3].
There was a decline in retreatment cases particularly
from 2012 to 2013 where the proportion of re-treatment
cases decreased from 43.1 to 41.1%.
HIV-positive patients not on ART
Table 1b shows the characteristics by year of the
HIV-positive patients who were not on ART at the start
of TB treatment. The median age was 34 [IQR 29–
41 years] and 25,384 (52.1%) were female. In this cohort
there was also a decline in the proportion of
extra-pulmonary TB cases over the 5 years from 20.5%
in 2009 to 17.7% in 2013 but this decline was less than
in the patients on ART at the start of TB treatment.
Re-treatment cases were unchanged between 2009 and
2012 but decreased from 28.8% in 2012 to 24.7% in
2013. The median CD4 count in this cohort was 152
[IQR 69–281 cells/mm3] in 2009, rising to 176 [IQR 74–
319 cells/mm3] in 2012 but then decreasing to 162 [IQR
67–313 cells/mm3] in 2013.
When comparing the characteristics of the patients on
ART with the patients who were not on ART at the start
of TB treatment there were some differences between
the two groups with patients on ART at start of TB
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treatment recording a higher proportion of retreatment
TB cases compared to patients not on ART (43.1% vs
28.2%) and a higher proportion of extra-pulmonary TB
(21.3% vs 19.6%). The majority of patients in both
groups were female but more female patients were re-
corded on ART compared to not on ART (58.1% vs
52.1%) (Tables 1a and Table 1b).
The CD4 count distribution and ART uptake
Figure 1a shows the CD4 count distribution of the
patients who were on ART at the start of TB treat-
ment. The CD4 count distribution showed a small
year by year shift from CD4 count categories less
than 200 cells/mm3 to CD4 categories greater than
200 cells/mm3 with the greatest shift occurring in the
CD4 category of 101–200 cells/mm3. In the patients
who were not on ART at the start of TB treatment
(Fig. 1b), there was also a shift in CD4 count distri-
bution from the category 101–200 cells/mm3 to
categories higher than 200 cells/mm3 but this change
was far less pronounced.
ART uptake during TB treatment among those not on
ART at the start of TB treatment increased substantially
over the five year period from 37.0% in 2009 to 77.7% in
2013. However, when ART uptake was compared across
CD4 categories, in 2013 despite guidelines that pre-
scribed universal coverage for all HIV-positive TB pa-
tients, a greater proportion of patients with higher CD4
counts did not start ART: in the CD4 count category
from 0 to 200 cells/mm3, 17.9% of patients did not start
ART, in the category of 201–500 cells/mm3, 22.8% did
not start ART and in category > 500 cells/mm3, 36.8%
did not start ART. (data not shown).
Figure 2 shows ART status by CD4 count categor-
ies per 50 cell/mm3 increase for the years 2009,
2011 and 2013. Over the five year period, total ART
coverage of TB patients increased considerably both
through the increase in numbers of patients present-
ing on ART as well as substantial increases in ART
Table 1 Baseline characteristics by year of HIV-positive patients on ART (Section A) and not on ART (Section B) at the start of TB treatment
Start year 2009 2010 2011 2012 2013 Total
All HIV-positive patients 12,372 12,749 12,490 11,811 11,060 60,482
Section A.
HIV-positive patients on ART n (%) 1221 (9.9) 1617 (12.7) 2235 (17.9) 3322 (28.1) 3313 (30.0) 11,708 (19.4)
Age, years, median [IQR] 35 [29–41] 34 [29–40] 36 [30–41] 35 [30–42] 36 [30–42] 35 [30–41]
Gender
Female n (%) 746 (61.1) 980 (60.6) 1323 (59.2) 1870 (56.3) 1880 (56.7) 6799 (58.1)
Classification
New TB n (%) 678 (55.5) 888 (54.9) 1249 (55.9) 1890 (56.9) 1953 (58.9) 6658 (56.9)
Retreatment TB n (%) 543 (44.5) 729 (45.1) 986 (44.1) 1432 (43.1) 1360 (41.1) 5050 (43.1)
Category
PTB n (%) 885 (72.5) 1184 (73.2) 1725 (77.2) 2668 (80.3) 2758 (83.2) 9220 (78.7)
EPTB n (%) 336 (27.5) 433 (26.8) 510 (22.8) 654 (19.7) 555 (16.8) 2488 (21.3)
Median CD4 150 [74–242] 153 [75–254] 169 [80–290] 178 [80–315] 202 [91–348] 175 [81–305]
Section B.
HIV-positive patients not on ART n (%) 11,142 (90.1) 11,130 (87.3) 10,255 (82.1) 8,481 (71.8) 7,741 (70.0) 48,749 (80.6)
Age, years, median [IQR] 34 [28-40] 34 [28-40] 34 [29-41] 35 [29-41] 35 [29-41] 34 [29-41]
Gender
Female n (%) 5,839 (52.4) 5,973 (53.7) 5,367 (52.3) 4,313 (50.9) 3,892 (50.3) 25,384 (52.1)
Classification
New TB n (%) 7,957 (71.4) 7,930 (71.2) 7,259 (70.8) 6,035 (71.2) 5,830 (75.3) 35,011 (71.8)
Retreatment TB n (%) 3,185 (28.6) 3,200 (28.8) 2,996 (29.2) 2,446 (28.8) 1,911 (24.7) 13,738 (28.2)
Category
PTB n (%) 8,860 (79.5) 8,808 (79.1) 8,186 (79.8) 6,964 (82.1) 6,370 (82.3) 39,188 (80.4)
EPTB n (%) 2,282 (20.5) 2,322 (20.9) 2,069 (20.2) 1,517 (17.9) 1,371 (17.7) 9,561 (19.6)
Median CD4 count [IQR] 152 [69-281] 160 [72-289] 174 [78-308] 176 [74-319] 162 [67-313] 164 [72-300]
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uptake during TB treatment for all CD4 count cat-
egories. Overall total ART coverage for HIV-positive
TB patients during TB treatment increased from
45.0% in 2009 to 85.2% in 2013.
TB treatment outcomes
There was an increase in TB treatment success rates
over the 5 year period for both HIV positive TB pa-
tients who presented on ART (from 78.1 to 80.9%)
and patients who were not on ART (76.7 to 79.6%)
(Table 2). This was largely driven by a decrease in TB
case fatality. For the patients who presented with TB
while on ART, the TB case fatality decreased from
5.6% in 2009 to 4.7% in 2013 while for patients who
were not on ART, the TB case fatality decreased from
7.4% in 2009 to 5.2% in 2013.
Survival analysis
Figure 3 shows Kaplan–Meier plots of survival by year
for the HIV-positive patients on ART (Fig. 3a) and not
on ART at start of TB treatment (Fig. 3b). Survival by
year for the HIV-positive patients on ART at the start of
TB treatment was not significantly different over the
5 year period (p = 0.47) but for the patients not on ART
at the start of TB treatment, the year on year improve-
ment in survival was significant (p < 001).
Risk factors for mortality during TB treatment for patient
on ART and not on ART at the start of TB treatment
For patients on ART at the start of TB treatment, a mul-
tivariable analysis using Cox proportional hazard models
showed a higher risk of TB mortality associated with in-
creasing age (Adjusted hazard ratio (aHR) 1.28 per
10 years increase of age, 95% CI: 1.17–1.40, p < 0.001)
and a lower risk of TB mortality associated with new TB
(aHR 0.71, 95% CI: 0.61–0.84, p < 0.001) and increasing
CD4 counts (aHR 0.87 per increase of 50 cells/mm3,
95% CI: 0.84–0.89, p < 0.001). TB mortality was not as-
sociated with calendar year of treatment, gender or type
of TB. (Table 3).
Risk factors for TB mortality during TB treatment for
HIV-positive patient not on ART at the start of TB treat-
ment were increasing age, female gender, retreatment
TB, and extra-pulmonary TB (Table 4). An increase in
CD4 count was associated with a decrease in mortality
(aHR 0.82 per increase of 50 cells/mm3, 95% CI:
0.81–0.83, p < 001) and the initiation of ART during TB
treatment was most strongly associated with lower TB
mortality (aHR 0.39, 95% CI: 0.35–0.42, p < 0.001).
a
b
Fig. 1 CD4 count distribution per year by ART status: a On ART at start of TB treatment . b Not on ART at start of TB treatment
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Discussion
Despite a great increase in the estimated ART coverage
in Cape Town, the decrease in the HIV-positive adult
TB case load was modest (13.2%). The effect of the ART
treatment programme is apparent from the increase in
numbers presenting on ART at the start of TB treatment
and the upward shift in the CD4 count distribution of
these patients. This is further supported by the decline
in extra-pulmonary TB cases which is indicative of a less
immunocompromised patient population.
However in 2013, 70% of HIV-positive TB patients
were not on ART when presenting with TB, indicating
that despite the roll-out of an extensive HIV treatment
programme, TB still remained an important gateway to
HIV care. The CD4 count distribution of these patients
was largely unchanged with over 75% having a CD4 cell
count less than 350 cells/mm3. For these patients, the
multivariate analysis showed that ART uptake during TB
treatment was most strongly associated with decreased
TB mortality. Higher CD4 counts were also associated
with decreased mortality but over the five year period,
the rise in median CD4 count for patients who were not
on ART at the start of TB treatment was modest indicat-
ing that the improved mortality was most likely driven
by the considerable increase in ART uptake (37.0 to
77.7%). Total ART coverage for HIV-positive TB patients
during TB treatment increased from 45.0% in 2009 to
85.2% in 2013.
This represents a substantial programmatic improve-
ment in how TB/HIV coinfected patients have been
managed in Cape Town. The decline in TB case fatality
for TB patients who were not on ART from 7.4 to 5.2%
compares very favourably with other treatment pro-
grammes. In a systematic review and meta-analysis on
the impact of ART on mortality in HIV-positive patients
on TB treatment, Odone et al. reported an estimated
Fig. 2 CD4 count distribution by ART status for the year 2009, 2011
and 2013
Table 2 TB treatment outcomes by year for HIV-positive patients by ART status at start of TB treatment
Total Success n (%) Death n (%) Default n (%) Failure n (%) Transfer Out n (%) Not evaluated n (%)
HIV-positive patients (On ART at START)
2009 1221 954 (78.1) 68 (5.6) 101 (8.3) 3 (0.3) 42 (3.4) 53 (4.3)
2010 1617 1280 (79.2) 102 (6.3) 138 (8.5) 8 (0.5) 45 (2.8) 44 (2.7)
2011 2235 1799 (80.5) 134 (6.0) 192 (8.6) 8 (0.4) 69 (3.1) 33 (1.5)
2012 3322 2651 (79.8) 178 (5.4) 309 (9.3) 19 (0.6) 122 (3.7) 43 (1.3)
2013 3313 2681 (80.9) 156 (4.7) 305 (9.2) 15 (0.5) 96 (2.9) 60 (1.8)
HIV-positive patients (Not on ART at START)
2009 11,142 8546 (76.7) 826 (7.4) 1005 (9.0) 36 (0.3) 494 (4.4) 235 (2.1)
2010 11,130 8746 (78.6) 738 (6.6) 1009 (9.1) 40 (0.4) 449 (4.0) 148 (1.3)
2011 10,255 8135 (79.3) 619 (6.0) 977 (9.5) 24 (0.2) 363 (3.5) 137 (1.3)
2012 8481 6718 (79.2) 513 (6.1) 848 (10.0) 28 (0.3) 274 (3.2) 100 (1.2)
2013 7741 6162 (79.6) 403 (5.2) 731 (9.4) 23 (0.3) 265 (3.4) 157 (2.0)
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case fatality of 8–14% based on an analysis of 21 studies
in Africa, Asia and the United Kingdom [16].
The low case fatality rate in Cape Town should how-
ever be interpreted with caution as the default rate of
9.4% in 2013 could partially represent unascertained mor-
tality. The default rate however remained stable over the
five year period for TB patients who were not on ART at
the start of TB treatment. This confirms an overall abso-
lute improvement in treatment outcomes as reflected in
the higher combined cure and completion rate.
While the overall improvement in ART uptake from
2009 to 2013 was substantial, patients with higher CD4
counts in 2013 were less likely to start ART during TB
treatment than those with lower CD4 counts. This may be
partially due to the ART treatment guidelines which indi-
cate that ART can be delayed for up to two months in pa-
tients with higher CD4 counts but may also be due to
patient choice or clinicians’ practice [17]. While this is a
small portion of the total population of TB cases, it does
represent a missed opportunity to enrol patients on ART
Fig. 3 a Kaplan-Meier plot of survival by year for HIV-positive patients on ART at start of TB treatment (p = 0.47). b Kaplan-Meier plot of survival by
year for HIV-positive patients not on ART at start of TB treatment (p < 001)
Table 3 Univariable and multivariable analyses of factors associated with mortality for patients on ART at start of TB treatment
PYRS Deaths Univariable Multivariable
Characteristic HR (95% CI) P-value aHR (95% CI) P-value
Calendar year
2009 11,479 1400 1 1
2010 11,646 1275 1.11 (0.81–1.51) 0.51 1.18 (0.85–1.63) 0.32
2011 11,350 1135 1.06 (0.79–1.42) 0.71 1.17 (0.86–1.59) 0.32
2012 11,095 1099 0.95 (0.72–1.26) 0.74 1.07 (0.80–1.44) 0.64
2013 10,010 922 0.90 (0.68–1.20) 0.47 1.05 (0.77–1.42) 0.76
Age (per 10 years increase) 5581 634 1.27 (1.17–1.38) < 0.001 1.28 (1.17–1.40) < 0.001
Female gender 3232 329 1 1
Male gender 2349 305 1.28 (1.09–1.50) 0.002 1.02 (0.86–1.20) 0.84
Re-treatment TB 2606 340 1 1
New TB 2975 294 0.72 (0.61–0.83) < 0.001 0.71 (0.61–0.84) < 0.001
PTB 4411 494 1 1
EPTB 1170 140 1.06 (0.88–1.28) 0.56 1.05 (0.86–1.27) 0.43
CD4 (per increase of 50 cells/mm3) 5389 603 1
0.87 (0.84–0.89)
< 0.001 1
0.87 (0.84–0.89)
P < 0.001
PYRS person years, HR Hazard Ratio, aHR Adjusted Hazard Ratio, CI confidence interval, TB tuberculosis, PTB pulmonary tuberculosis, EPTB
extra-pulmonary tuberculosis
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and could be detrimental to their long term prognosis par-
ticularly if ART is not started after the TB episode.
While this study shows improved ART uptake during
TB treatment and improved TB treatment outcomes, the
relatively small reduction in the HIV-positive TB case load
does not provide support for ART as a highly effective
method for curtailing the population TB case load. This is
consistent with our recent evaluation of trends in TB noti-
fication rates during ART scale-up in Cape Town [9]. This
is also supported by a number of modelling scenarios that
indicate a limited effect of ART on TB incidence unless
scale-up encompasses near universal coverage for all
HIV-positive patients. [18–20].
The limitations of this study are the retrospective study
design and the reliance on programmatic data. This is par-
ticularly apparent in the reported decline in retreatment
cases from 2012 to 2013 which coincided with the phasing
out of streptomycin in 2013 and may be due to an ascer-
tainment error as retreatment cases were often identified
by the inclusion of streptomycin in the TB treatment regi-
men [14]. A further limitation is that the data cut-off point
for this study was end December 2013 and our findings
therefore may not reflect the current TB prevalence and
treatment outcomes in Cape Town.
Conclusion
This study showed comprehensive changes in the ART
and TB treatment programmes resulted in incremental
increases in ART coverage for HIV-positive TB patients
and a subsequent decrease in TB case fatality due to in-
creased ART uptake in HIV-positive ART-naïve TB pa-
tients. However TB still remained a major presenting
opportunistic infection with the majority of cases occur-
ring at low CD4 counts.
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Table 4 Univariable and multivariable analyses of factors associated with mortality for patients who were not on ART at start of TB
treatment
PYRS Deaths Univariable Multivariable
Characteristic HR (95% CI) P-value aHR (95% CI) P-value
Calendar year
2009 5169 823 1 0.03 1 0.38
2010 5163 733 0.89 (0.81–0.98) < 0.001 1.05 (0.94–1.18) 0.66
2011 4769 616 0.81 (0.73–0.90) < 0.001 1.03 (0.91–1.16) 0.09
2012 3943 512 0.82 (0.73–0.91) < 0.001 1.12 (0.98–1.27) 0.55
2013 3361 401 0.73 (0.65–0.83) 1.04 (0.91–1.21)
Age (per 10 years increase) 22,405 3085 1.34 (1.30–1.39) < 0.001 1.38 (1.32–1.44) < 0.001
Female gender 11,662 1528 1 0.004 1 0.004
Male gender 10,743 1557 1.11 (1.03–1.19) 0.89 (0.82–0.96)
Re-treatment TB 7142 1122 1 1
New TB 15,263 1963 0.76 (0.71–0.82) < 0.001 0.67 (0.62–0.73) < 0.001
PTB 18,083 2391 1 1
EPTB 4321 694 1.20 (1.11–1.31) < 0.001 1.25 (1.14–1.38) < 0.001
CD4 (per increase of 50 cells/mm3) 21,574 2807 0.85 (0.84–0.86) < 0.001 0.82 (0.81–0.83) < 0.001
Did not start ART 7037 1254 1 1
Started ART 13,145 1301 0.56 (0.52–0.61) < 0.001 0.39 (0.35–0.42) < 0.001
PYRS person years, HR Hazard Ratio, aHR Adjusted Hazard Ratio, CI confidence interval, TB tuberculosis, PTB pulmonary tuberculosis, EPTB extra-pulmonary
tuberculosis, ART antiretroviral therapy
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